3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
9
Carcinoma, Hepatocellular
9
Small Cell Lung Carcinoma
8
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Glioblastoma
5
Carcinoma, Transitional Cell
5
Ovarian Neoplasms
4
Advanced Solid Tumor
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Liver Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Neuroendocrine
3
Solid Cancer
2
Small Cell Lung Cancer Extensive Stage
2
Recurrence
2
Neuroendocrine Tumors
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
atezolizumab
2
Etoposide
2
Carboplatin
2
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Cancer Extensive Stage
×
atezolizumab
×
Clear all
NCT05703971
2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2
Recruiting
62 enrolled
NCT07227597
2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled